Study guide

10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze

Key Takeaways Explain This Topic AI

Assessment of paediatric respiratory distress relies on work of breathing (subcostal/intercostal recession, sternal indrawing, tracheal tug, nasal flaring, grunting) and age-specific tachypnoea thresholds (<2 months: >60/min; 2–11 months: >50/min; 1–5 years: >40/min).

Croup (laryngotracheobronchitis) is predominantly caused by parainfluenza virus in children aged 6 months to 3 years; oral dexamethasone (0.15 mg/kg stat) is the definitive first-line treatment for all severities, while severe croup requires nebulised adrenaline (1:1000) under close observation.

Acute epiglottitis (Haemophilus influenzae type b) is a life-threatening airway emergency characterized by toxic appearance, high fever, tripod position, drooling, and absent cough; direct examination or throat instrumentation is strictly forbidden, requiring immediate senior anaesthetic and ENT airway control in theatre.

Bronchiolitis is primarily driven by respiratory syncytial virus (RSV) in infants under 1 year (peak 3–6 months); clinical management is purely supportive (humidified oxygen for SpO2 <92% and NG/IV fluids for feed intake <50%), with NICE explicitly recommending against bronchodilators, corticosteroids, or antibiotics.

Preschool wheeze is predominantly viral-induced wheeze (VIW) lacking interval symptoms or atopic features; acute severe wheeze is treated with titrated inhaled salbutamol via spacer (up to 10 puffs), oral prednisolone (10–20 mg), and emergency escalation to nebulised bronchodilators or IV magnesium sulphate if failing to improve.

Last updated: October 2026

Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze

Respiratory tract pathology represents the leading cause of emergency paediatric presentations and acute hospital admissions in the United Kingdom. Because young children possess narrow subglottic airways, high compliance of the cartilaginous thoracic cage, and high baseline metabolic demands, respiratory distress can rapidly transition to respiratory muscle exhaustion and catastrophic respiratory failure. Differentiating upper airway obstruction (stridor) from lower airway obstruction (wheeze and crackles) is the cornerstone of clinical evaluation.

Assessment of Paediatric Respiratory Distress

Clinical evaluation must assess the work of breathing , airway patency , physiological compromise , and respiratory exhaustion .

Clinical Signs of Increased Work of Breathing

Tachypnoea: The earliest and most reliable compensatory sign of paediatric respiratory compromise. Thresholds defined by the Advanced Paediatric Life Support (APLS) framework:

  • < 2 months: > 60 breaths/minute
  • 2 to 11 months: > 50 breaths/minute
  • 1 to 5 years: > 40 breaths/minute
  • > 5 years: > 30 breaths/minute

Chest Wall Recession: Negative intrathoracic pressures generated against airway resistance lead to dynamic inward collapse of compliant tissues:

Subcostal recession: Indrawing below the lower costal margin.

Intercostal recession: Inward movement of intercostal spaces.

Sternal indrawing: Retraction of the sternum (sign of severe distress).

Tracheal Tug: Inferior downward displacement of the thyroid cartilage and suprasternal notch during inspiration.

Nasal Flaring: Dilatation of the alae nasi to reduce upper airway resistance.

Expiratory Grunting: Forced expiration against a partially closed glottis to generate physiological positive end-expiratory pressure (PEEP), preventing alveolar collapse and maintaining functional residual capacity (FRC). Grunting is an ominous red-flag sign of impending respiratory failure.

Head Bobbing: Scalene and sternocleidomastoid contractions pulling the head forward with each breath in exhausted infants.

Upper Airway Emergencies: Croup vs Acute Epiglottitis

Upper airway obstruction produces inspiratory stridor —a harsh, high-pitched vibratory sound arising from turbulent airflow through narrowed extrathoracic airways.

Diagnostic Feature Croup (Laryngotracheobronchitis) Acute Epiglottitis

Primary Aetiology Parainfluenza virus (types 1, 2, and 3 account for ~75%); RSV, influenza Haemophilus influenzae type b (Hib) ; Streptococcus pneumoniae; Staphylococcus aureus

Typical Age Range 6 months to 3 years (peak around 1–2 years) 2 to 7 years (unimmunised or partially immunised children)

Onset & Progression Gradual onset over 1–3 days; preceded by coryzal symptoms Hyperacute, rapid progression over hours; no prodrome

Toxic Appearance & Fever Generally non-toxic; low-grade pyrexia (< 38.5°C) Severely toxic, septic appearance; high fever (> 39.0°C)

Cough & Voice Loud, barking "seal-like" cough ; hoarse voice Absent or minimal cough ; muffled, soft "hot potato" voice

Posture & Salivation Restless or agitated; swallowing preserved, no drooling Sitting upright in "tripod" position, neck extended; prominent drooling (dysphagia/odynophagia)

Emergency Throat Exam Safe to inspect if necessary without agitating child STRICTLY FORBIDDEN: Do not inspect or use tongue depressor!

Croup (Laryngotracheobronchitis) Management

Croup involves inflammatory mucosal oedema of the larynx, trachea, and subglottic space. Symptoms characteristically worsen late at night.

Severity Stratification (Westley Score):

Mild: Occasional barking cough, hoarseness, no stridor at rest, no or mild recession.

Moderate: Frequent barking cough, easily audible stridor at rest, intercostal and subcostal recession, child irritable but consolable.

Severe: Prominent inspiratory stridor at rest, sternal indrawing, marked agitation or lethargy, tachypnoea, signs of fatigue.

Definitive Pharmacotherapy: A single oral dose of dexamethasone (0.15 mg/kg) is indicated for all severities of croup (mild, moderate, and severe). It significantly reduces hospital admissions, the need for nebulised adrenaline, and repeat presentations. If vomiting, oral prednisolone (1–2 mg/kg) or nebulised budesonide (2 mg) can be substituted.

Severe Croup / Impending Airway Exhaustion:

Administer nebulised adrenaline (1:1000, 0.5 mL/kg up to a maximum of 5 mL) with high-flow oxygen.

Adrenaline acts rapidly on alpha-adrenergic receptors to induce subglottic arteriolar vasoconstriction, shrinking mucosal oedema within 10–30 minutes.

Safety Precautions: Keep the child calm on the parent's lap; crying drastically increases turbulence and accelerates obstruction. Adrenaline has a short duration of action (~2 hours) and mucosal rebound can occur; observe continuously for at least 4 hours post-nebulisation.

Acute Epiglottitis Management

Acute epiglottitis is a medical and surgical emergency causing supraglottic cellulitis and massive oedema of the lingual surface of the epiglottis, aryepiglottic folds, and arytenoids.

The Golden Rule: DO NOT examine the throat with a tongue depressor, attempt venepuncture, or force the child into a supine position. Any invasive agitation can trigger immediate, fatal laryngospasm and complete airway occlusion.

Immediate Escalation: Immediately summon the most senior paediatrician, consultant anaesthetist, and senior ENT surgeon.

Airway Control in Theatre: Transfer the child calmly in the parent's arms directly to the operating theatre for urgent endotracheal intubation under gentle inhalational anaesthesia (sevoflurane).

Antimicrobial Therapy: Following definitive airway securing, obtain blood cultures and initiate intravenous ceftriaxone (80 mg/kg) .

Lower Airway Disorders: Bronchiolitis vs Preschool Wheeze

Lower airway obstruction causes expiratory airflow limitation, resulting in prolonged expiration and wheezing (a musical, polyphonic adventitious sound).

Bronchiolitis

Bronchiolitis is an acute viral infection of the lower respiratory tract leading to inflammatory epithelial necrosis, ciliary denudation, peribronchiolar lymphocytic infiltration, and mucus plugging of the terminal bronchioles.

Epidemiology & Aetiology: Predominantly driven by Respiratory Syncytial Virus (RSV) in > 75% of cases (others include rhinovirus and human metapneumovirus). Affects infants under 1 year of age , peaking between 3 and 6 months during winter.

Prevention: Since September 2024 the UK offers RSV vaccination in pregnancy from 28 weeks (antibodies cross the placenta to protect the infant in the first months of life); high-risk infants (for example those born very preterm or with haemodynamically significant congenital heart disease) may also receive a monoclonal antibody (palivizumab or nirsevimab) according to Green Book criteria.

Clinical Presentation: Commences with a 1- to 3-day viral prodrome of coryza, clear rhinorrhoea, and mild fever, progressing to a persistent dry, harsh wheezy cough, tachypnoea, chest indrawing, and feeding difficulties. Auscultation reveals bilateral fine inspiratory crackles and diffuse high-pitched expiratory wheezes across all lung zones.

NICE NG9 Admission Criteria:

Oxygen saturation consistently < 92% in room air.

Inadequate fluid intake (< 50% of normal daily intake over preceding 24 hours).

Witnessed or reported apnoea.

Severe respiratory distress (grunting, marked chest recession, or a respiratory rate over 70/min; NICE NG9).

High-risk co-morbidities: Prematurity (< 32 weeks), congenital heart disease, chronic lung disease of prematurity (bronchopulmonary dysplasia).

Evidence-Based Management (Supportive Care):

Oxygenation: Humidified supplemental oxygen via nasal prongs to maintain SpO2 ≥ 92%.

Hydration & Nutrition: Nasogastric (NG) tube feeding if oral intake is 50% or less; intravenous isotonic fluids (0.9% saline with 5% glucose) if enteral feeding is unsafe due to respiratory distress or vomiting.

What NOT to Prescribe (NICE Negative Guidance): Extensive clinical trials confirm that salbutamol, systemic or inhaled corticosteroids, nebulised adrenaline, montelukast, and antibiotics provide NO clinical benefit in bronchiolitis and must NOT be routinely prescribed.

Preschool Wheeze vs Paediatric Asthma

Wheezing in preschool children (< 5 years) is extremely prevalent, occurring in up to one-third of children. It is essential to differentiate viral-induced wheeze from true emerging paediatric asthma.

Clinical Characteristic Viral-Induced Wheeze (VIW) Paediatric Asthma / Multi-Trigger Wheeze

Triggers Exclusively viral upper respiratory tract infections Viral infections PLUS exercise, cold dry air, animal dander, house dust mites, emotional crying

Interval Symptoms Completely asymptomatic between viral colds; no cough or wheeze Persistent interval symptoms: Nocturnal waking with cough, early morning wheeze, exercise limitation

Atopic Background No personal history of eczema or allergic rhinitis; negative family history of atopy Personal history of atopic eczema or food allergies; strong first-degree family history of asthma/atopy

Long-Term Prognosis Benign natural history; typically resolves completely by age 5–6 as airway calibre enlarges Often persists into middle childhood and adolescence; represents true chronic airway inflammation

Acute Management of Paediatric Wheeze (BTS/SIGN & NICE Guidelines)

When a child over 1 year presents with acute wheeze, management follows a standardized, escalating protocol:

Inhaled Beta-2 Agonist: Administer salbutamol via a metered-dose inhaler (MDI) with a volume spacer and facemask :

Mild-to-moderate wheeze: 2 to 6 puffs.

Severe wheeze: Up to 10 puffs (administered as 1 puff every 30–60 seconds, with the child breathing 5 normal tidal breaths per puff).

Oral Systemic Corticosteroids: Indicated for moderate-to-severe exacerbations:

Oral prednisolone for 3 days:

Age < 2 years: 10 mg daily.

Age 2 to 5 years: 20 mg daily.

Age > 5 years: 30–40 mg daily.

Controlled Oxygen Therapy: High-flow oxygen via Hudson mask or reservoir bag to maintain target saturation 94% to 98% .

Second-Line Escalation (Severe / Refractory Wheeze):

Nebulised bronchodilators: Back-to-back nebulised salbutamol (2.5 mg for < 5 years; 5 mg for ≥ 5 years) driven by oxygen, combined with nebulised ipratropium bromide (250 mcg) every 20–30 minutes for the first hour.

Intravenous Magnesium Sulphate (40 mg/kg, max 2 g) infused over 20 minutes to achieve bronchial smooth muscle relaxation.

Intravenous aminophylline or intravenous salbutamol in a High Dependency Unit (HDU) or Paediatric Intensive Care Unit (PICU) under continuous ECG and hemodynamic monitoring.

Loading diagram... Paediatric Respiratory Distress Assessment & Airway Algorithm